Introduction: Topical nasal steroids are the main therapeutic otpion for controlling inflammation in rhinitis. Objectives: To assess acceptability, tolerance and effectiveness of nasal beclomethasone in single daily dose in the treatment of allergic rhinitis. Methods: This open, multicenter and collaborative clinical study was accomplished with a new formulation of beclomethasone dipropionate 100 µg, for the administration in once a day dose in the treatment of the allergic rhinitis. A total of 263 patients with allergic rhinitis were included and completed the period of clinical evaluation (acceptability, effectiveness and tolerability parameters), following treatment for two weeks. Results: Intranasal beclomethasone 100 µg provided excellent and good clinical effectiveness in 95% of its patients. The acceptability of its use was considered excellent and good in 97% of the cases. The sum of all the scores of the signs and isolated symptoms supplied the global clinical score. The accomplished evaluations 7 and 14 days after the beginning of the treatment evidenced a significant reduction in the global score in relation to the evaluation accomplished before the beginning of treatment. The tolerability was considered good and excellent in most patients (98.5%). Undesirable events were reported in 18 patient (6.8%). Most of the reactions were considered of mild intensity, not determining abandonment to the treatment. Conclusion: Beclomethasone 100 µg once a day provides high indexes of effectiveness and acceptability and a favorable tolerability profile in allergic rhinitis patients.